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Atherosclerosisarker of atherosclerosis and inﬂammation. The objective of this study was to
determine the direct effects of free nitrotyrosine on human aortic smooth muscle cell (AoSMC) migration and
molecular mechanisms. By a modiﬁed Boyden chamber assay, nitrotyrosine signiﬁcantly increased AoSMC
migration in a concentration-dependent manner. For example, nitrotyrosine at 300 nM increased AoSMC
migration up to 152% compared with L-tyrosine-treated control cells (Pb0.01). Cell wound healing assay
conﬁrmed this effect. Nitrotyrosine signiﬁcantly increased the expression of some key cell migration-related
molecules including PDGF receptor-B, matrix metalloproteinase 2 (MMP2) and integrins αV and β3 at both
mRNA and protein levels in AoSMC (Pb0.01). In addition, nitrotyrosine increased reactive oxygen species
(ROS) production in AoSMC by staining with ﬂuorescent dye DCFHDA. Furthermore, nitrotyrosine induced
transient phosphorylation of ERK2 by Bio-Plex luminex immunoassay and western blot analysis. AoSMC were
able to uptake nitrotyrosine. Antioxidants including seleno-L-methionine and superoxide dismutase mimetic
(MnTBAP) as well as ERK1/2 inhibitor PD98059 effectively blocked the promoting effect of nitrotyrosine on
AoSMC migration and the mRNA expression of above cell migration-related molecules. Thus, nitrotyrosine
directly increases AoSMC migration in vitro and the expression of migration-related molecules through
overproduction of ROS and activation of ERK1/2 pathway. Nitrotyrosine may contribute to cardiovascular
pathogenesis.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Increased levels of both circulating free nitrotyrosine and protein-
combined nitrotyrosine are commonly found in many pathological
conditions [1,2]. Many studies have demonstrated that protein nitration
is evidenced in human atherosclerotic tissues, associated with different
stages of atherosclerosis, and even correlated with plaque instability in
patients [3,4]. Increased nitrotyrosine is also observed in the vascular
remodeling with neointima formation [5]. More clinical studies have
shown that plasma levels of nitrotyrosine can serve as an independent
predictor of risk for coronary artery disease and atherosclerotic burden,
and are modulated by known cardiovascular disease (CVD) risk-
reducing therapies such as statins [6]. Thus, nitrotyrosine becomes a
new biomarker for cardiovascular disease. However, there are few
studies on the direct role of nitrotyrosine in the vascular system.
Migration andproliferation of vascular smoothmuscle cells (VSMC)
are the key processes of neointima formation in many vascular
pathogenesis such as atherosclerosis, restenosis after angioplasty,nt of Surgery, Baylor College of
on, TX 77030, USA. Tel.: +1 713
l rights reserved.and saphenous vein graft failure [7]. VSMC may contribute to the
development of atherosclerosis through the production of inﬂamma-
tory cytokines such as monocyte chemoattractant protein-1, and the
synthesis of matrix proteins [8]. These processes involve the inter-
action of VSMCs with matrix and changes in intracellular signal-
ing pathways that regulate cell migration. Platelet-derived growth
factor-BB (PDGF-BB) is a major regulator of VSMC migration. Matrix
metalloproteinases (MMP) and integrins provide permissive effects for
VSMCmigration by breaking downmajor extracellular barriers such as
basalmembranes, interstitial collagens, and proteoglycans [9], thereby
playing an essential role in regulating VSMC migration.
Reactive oxygen species (ROS), generated by a variety of extra-
cellular and intracellular mechanisms, have gained attention as novel
signal mediators that regulate signal transduction events including
mitogen-activated protein kinases (MAPKs) [10]. ROS integrate
cellular signaling pathways involved in VSMC proliferation and
migration associated with atherosclerosis [11]. Antioxidants are
believed to counteract with ROS and reduce the incidence of coronary
artery disease [12]. Seleno-L-methionine (SeMet) is an effective
antioxidant by increasing the activity of glutathione peroxidase [13]
and other mechanisms. Mn (III) tetrakis (4-benzoic acid) porphyrin
(MnTBAP) is a cell permeable superoxide dismutase (SOD) mimetic,
which is used as a potent superoxide anion scavenger [14].
Table 1
Sequence details of individual pairs of primers
Gene Gene bank no. Forward primer Reverse primer
PDGFR-B NM_002609 CCTTACCACATCCGCTCCATCC CATTCACACTCTCCGTCACATTGC
MMP2 AY738117 CAACTACAACTTCTTCCCTCGCA GGTCACATCGCTCCAGACTTG
Integrin αv NM_002210 GATTTCTTCGTGCCCAGCG GCGGGTAGAAGACCAGTCAC
Integrin β3 NM_000212 ATGCTTCATCCATCATCGGTGTC GGTCACCTGGTCAGTTAGCGT
β-actin BC013835 CTGGAACGGTGAAGGTGACA GGAAGCACTTCCTGGACTTGAT
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functions of nitrotyrosine in vascular cell migration, which may con-
tribute to vascular lesion formation. Human aortic smoothmuscle cells
(AoSMC) were treated with free nitrotyrosine, and the cell migration
and the expression of PDGF receptor-B (PDGFR-B), MMP and integrins
as well as involvement of ROS generation and MAPK activation were
investigated. The data from this study provide experimental evidence
of the direct effects of free nitrotyrosine on human AoSMC migration
with unique molecular mechanisms.
2. Materials and methods
2.1. Chemicals and reagents
3-Nitrotyrosine (FW 226.2) was purchased from Cayman Chemical Company (Ann
Arbor, Michigan). L-tyrosine was purchased from Sigma-Aldrich (St. Louis, MO). Anti-
human integrin β3 (CD61) and integrin αV were purchased from BD Biosciences
Pharmingen (San Diego, CA). Anti-human β-actin antibody and SeMet were obtained
from Sigma-Aldrich. Human PDGF-BB and anti-human PDGFR-B antibody were from
R&D Systems, Inc. (Minneapolis, MN). Extracellular signal-regulated kinase (ERK)Fig. 1. Effect of nitrotyrosine on human AoSMC migration. (A) Concentration-dependen
transwell plate with different concentrations of nitrotyrosine (0–3000 nM). After 24 h incu
calcein-AM, staining and quantitation. L-tyrosine was used as a negative control. Results ar
the migrated cells to the lower chamber after calcein-AM staining. L-tyrosine (300 nM), nit
course study by Boyden chamber assay. Serum-starved AoSMC were seeded onto the trans
8, 16, and 24 h. Each bar represents the mean±SEM. ⁎Pb0.05 and ⁎⁎Pb0.01 compared with
cell wound healing assay. Conﬂuent AoSMCwere wounded by a scratch injury line madewi
(300 nM); or PDGF-BB (10 ng/ml). Photos were taken at 16 h. Dotted white lines delimit the
(10 ng/ml) as a positive control are shown.inhibitor (PD98059) and calcein-AM were obtained from Calbiochem Inc. (San Diego,
CA). MnTBAP was purchased from A.G. Scientiﬁc (San Diego, CA).
2.2. Cell culture
AoSMC (Walkersville, MD) were routinely cultured in Smooth Muscle Medium-2
(SmGM-2) with growth factors and antibiotic (SmGM-2 Bullet Kit) supplemented with
10% fetal calf serum (FCS). Prior to each experiment, AoSMCwere placed in the SmGM-2
medium with 1% FCS, without addition of growth factors, for 16 h (serum starvation).
AoSMC were used between passages 3 and 7.
2.3. Cell migration assay
Cell migration was measured by using a modiﬁed Boyden chamber assay including
Fluoroblock transwell migration plates (Becton Dickinson Labware, Franklin Lakes, NJ).
Brieﬂy, serum-starved cell suspension (250 μl, 1×105 cells/well) was added to the upper
chamber of the FlouroBlock transwell insert (24-well plate). After 4 to 24 h incubation at
37 °C in a 5% CO2 atmosphere, the chambers were incubated in Hank's Balanced Salt
Solution (HBSS) with 50 nM calcein-AM, a ﬂuorescence dye to label living cells. The
ﬂuorescence of the cells migrated to the lower chamber was measured from the bottom
using a ﬂuorescence microplate reader at 485/535 nM wavelength. The migrated cells in
the ﬁlters were also observed under a ﬂuorescence microscope (Olympus, Tokyo, Japan).t study in the Boyden chamber assay. Serum-starved AoSMC were seeded onto the
bation, AoSMC migrated to the lower chamber were measured by a ﬂuorescence dye,
e expressed as percentage of the control. (B) The representative photomicrographs of
rotyrosine (300 nM) and PDGF-BB (10 ng/ml) as a positive control are shown. (C) Time
well plate with 300 nM nitrotyrosine or L-tyrosine. AoSMC migrationwas studied at 4,
the control (L-tyrosine). n=4 per group. (D) The representative photomicrographs of
th a sterile cell scraper. Cells were then treated with L-tyrosine (300 nM); nitrotyrisine
initially wounded regions. L-tyrosine (300 nM), nitrotyrisine (300 nM), and PDGF-BB
Fig. 2. Effects of nitrotyrosine on the expression of VSMC migration-related molecules
and MMP2 activity. Serum-starved AoSMC were treated with nitrotyrosine (300 nM) or
L-tyrosine (300 nM) for 24 h. (A) Real-time PCR analysis. The cDNA was synthesized
from total mRNA of the treated cells by reverse transcription. The mRNA levels of
PDGFR-B, integrin β3, integrinαV, andMMP2were analyzed by real-time PCR andwere
normalized to the housekeeping gene β-actin as [2(Ct β-actin −Ct gene of interest)]. Values are
expressed as percentage of the non-treated control. (B) Western blot analysis of protein
levels of PDGFR-B, integrin αV, and integrin β3 in AoSMC. Equal amount of 15 µg cell
lysate proteins was used to run western blotting against human PDGFR-B, integrin αV,
and integrin β3. The band density was measured with AlphaEaseFC 3.1.2 software and
normalized to β-actin levels. (C) MMP2 activity in the supernatants of AoSMC cultures.
Serum-starved AoSMCwere treated with nitrotyrosine (300 nM) or L-tyrosine (300 nM)
for 24 h. One hundred microgram of proteins from each concentrated cell supernatant
was analyzed byMMP2 activity assay. After activated by APMA for 15 min at 37 °C, 50 µl
of a ﬂuorogenic FRET conjugated MMP2 substrate solution was added and incubated
for 30 min at room temperature. The ﬂuorescence intensity representing the MMP2
activity was measured at 485/535 nM wavelength. Results are expressed as percentage
of controls (L-tyrosine). Data represent as mean ± SEM. ⁎Pb0.05. ⁎⁎Pb0.01. n=3.
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AoSMCwere grown to 90% conﬂuence in six-well plates, a scratch was made with a
sterile cell scraper. The starting point was marked with a marker pen at the bottom
of the plate. Cells were washed with basal medium twice and were incubated with
L-tyrosine (300 nM) or nitrotyrosine (300 nM), or PDGF-BB (10 ng/ml) in the basal
medium. The cells were incubated for 16 h and stained with calcein-AM [15]. Photos
were taken using ﬂuorescence microscope.
2.5. RNA isolation and real-time RT-PCR
Serum-starved AoSMC were treated with nitrotyrosine (300 nM) or L-tyrosine
(300 nM) for 24 h, and total RNAwas isolated using Trizol reagent and then treated with
TURBO™ DNase (RNase-free) (Ambion, Austin, TX). One μg of total RNA was reverse-
transcribed in 20 μl reaction solution using the iScript™ cDNA Synthesis Kit. Human
PDGFR-B, MMP, and integrins as well as β-actin primers were designed using Beacon
Designer software (Table 1). Real-time PCR reactions were performed with the iCycler
iQ Real-Time PCR Detection System (Bio-Rad Laboratories) in 96-well reaction plates.
Reaction volumewas 25 μl, containing 2 μl cDNA and 100 μMof each pair of primers and
iQ™ SYBR Green Supermix (Bio-Rad). Thermal cycling condition included pre-
incubation 95 °C for 3 min followed by 40 PCR cycles at 95 °C for 20 s and 60 °C for
1 min. The iCycler software was used to analyze the calibration curve by plotting the
threshold cycle (Ct) versus the logarithm of the number of copies for each calibrator.
The quality and quantities of samples were normalized to the housekeeping gene
β-actin as [2(Ct β-actin − Ct gene of interest)].
2.6. ROS measurement
ROS generation was determined by ﬂow cytometry analysis of DCFHDA oxidation
[16,17], which is widely used to measure oxidative stress in cells due to the high
sensitivity of ﬂuorescence-based assays. The assay consists of the oxidation of DCFHDA
(after hydrolysis of the diacetate form) to ﬂuorescein by ferryl-type intermediates and/
or oxygen and nitrogen reactive species, whose ﬂuorescence can be measured at
522 nM. Following treatments with nitrotyrosine (300 nM) or L-tyrosine (300 nM),
with/without SeMet (20 µM) or MnTBAP (3 µM) for 30 min, AoSMC were collected by
trypsinization, washed, and incubated with 20 µM 2′,7′-dichloroﬂuorescin diacetate
(DCFHDA, Invitrogen, CA) for 20 min. Intracellular ROS generationwas assessed by ﬂow
cytometric monitoring of DCFHDA oxidation. Mean ﬂuorescence intensity (MFI) was
recorded. DCFHDA oxidation was also directly measured in a ﬂuorescent microplate
reader using excitation and emission wavelengths of 485 and 535 nM.
2.7. MAPK activation
The MAPK phosphorylation state of AoSMC was analyzed by Bio-Plex phospho-
protein and total target assays (Bio-Rad) according to manufacturer's instructions.
Brieﬂy, serum-starved AoSMC were treated with nitrotyrosine (300 nM) or L-tyrosine
(300 nM), and the cell lysates were collected at different time points of 0, 5, 10, 20, 30,
and 60 min with the Bio-Plex Cell Lysis Kit. The protein concentration was adjusted to
600 μg/ml, and 50 μl of cell lysate was used for each assay. Fifty μl of coupled beads,
which recognize phosphorylated and total ERK2, p38, and JNK, respectively, was added
to the 96-well ﬁlter plate. Same volume of the cell lysate was added and incubated with
the beads for 15–18 h. Then, 25 µl of detection antibodies (1x) was added and incubated
for 30 min. Fifty μl of streptavidin-PE (1x) was added and incubated for 10 min in dark.
The phosphoprotein and total proteins of MAPKs were analyzed by a Luminex 100TM
analyzer (Bio-Rad).
2.8. Western blotting
AoSMC were treated with nitrotyrosine (300 nM) or L-tyrosine (300 nM) for 24 h,
and the cell lysates were collected using cell lysate buffer (Cell Signaling Technology,
Danvers, MA). Fifteen micrograms of lysate proteins was loaded for Western blot
analysis. Total cellular proteins were separated by 10% SDS-polyacrylamide gel elec-
trophoresis and then transblotted overnight at 4 °C onto Hybond-P PVDF membrane.
After blocking themembranewith 5%nonfat driedmilk, themembranewas probedwith
the respective primary antibodies against human integrin αV, MMP2, and PDGFR-B,
p22phox, p47phox, phosphorylated ERK2, and total ERK2 respectively, at room tem-
perature for 1 h. The membranes were then incubated in the horseradish peroxidase-
linked secondary antibody for 50 min at room temperature. The immunoreactive bands
were detected by enhanced chemiluminescent (ECL) plus reagent kit. The band density
was measured with the use of AlphaEaseFC 3.1.2 software (Alpha Innotech Corporation,
San Leandro, CA).
2.9. MMP2 activity assay
MMP2 activity was determined by the EnzoLyte™ 490 MMP2 Assay Kit from
AnaSpec Co. (San Jose, CA) in a 96-well plate. Brieﬂy, the supernatants of AoSMC
cultures were collected and concentrated in YM-10 columns for 30 min. One hundred
microgram proteins in 50 µl of the concentrated supernatant were used for each assay.
After activated by p-aminophenylmercuric acetate (APMA) for 15 min at 37 °C, 50 µl of a
ﬂuorogenic [an EDANS/DABCYL ﬂuorescence resonance energy transfer (FRET) peptide]
MMP2 substrate solutionwas added and the reactionwas incubated for 30 min at room
Fig. 4. Effects of antioxidants SeMet and MnTBAP on nitrotyrosine-induced AoSMC
migration increase and NADPH oxidase expression. Serum-starved AoSMCwere seeded
onto the transwell plate and incubated with nitrotyrosine (300 nM) or L-tyrosine
(300 nM), with the presence or absence of SeMet (20 µM) (A) or MnTBAP (3 µM) (B).
After 24 h incubation, AoSMC migrated to the lower chamber were measured by
calcein-AM staining and quantitation. Results are expressed as percentage of controls
(L-tyrosine). n=4. (C) Expression of NADPH oxidase subunits (p47 phox) in AoSMC after
nitrotyrosine and L-tyrosine treatment by western blot analysis. The band density
was measured with AlphaEaseFC 3.1.2 software and normalized to β-actin levels. Data
represent as mean ± SEM. ⁎Pb0.05. n=3.
Fig. 3. Roles of ROS in nitrotyrosine-induced AoSMC migration. The cells were treated
with nitrotyrosine (300 nM) or L-tyrosine (300 nM), with or without SeMet (20 µM) or
MnTBAP (3 µM) for 30 min. Then the cells were stained with DCFHDA and analyzed by
ﬂow cytometry or a ﬂorescence plate reader. (A) Quantitation of DCFHDA oxidation and
ﬂow cytometry analysis (mean ﬂuorescence intensity, MFI). (B) DCFHDA oxidation assay
by a ﬂorescence plate reader. Each bar represents the mean±SEM. ⁎Pb0.05 compared
with the control (L-tyrosine). n=4 per group.
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at 485/535 nM wavelength.
2.10. Immunocytochemistry
AoSMCwere treatedwith nitrotyrosine (300 and 3000 nM) or L-tyrosine (3000 nM)
for 24 h, and the cells were ﬁxed in 4% paraformaldehyde, preincubated in 0.3% Trition-X
in PBS at room temperature for 15min. After blocking in 1.5% blocking serum for 1 h, the
cells were incubated in rabbit anti-nitrotyrosine antibody (Millipore Corporation, TX)
solution overnight at 4 °C. Expression was detected using FITC-conjugated goat anti-
rabbit IgG secondary antibody (R&D Systems, Inc., MN) and the cells were observed
under a ﬂorescence microscope (Olympus, Tokyo, Japan).
2.11. Statistical analysis
Data are presented as mean±SEM in all experiments. Data from treated groups
were compared with control groups by a Student's t-test (two tailed). A value of Pb0.05
was considered signiﬁcant.
3. Results
3.1. Nitrotyrosine promotes human AoSMC migration
To investigate the effect of nitrotyrosine on AoSMC migration,
cells were treated for 24 h with increasing concentrations of
nitrotyrosine (0.3–3000 nM) or L-tyrosine (3000 nM) as a negative
control in the upper chamber of a modiﬁed Boyden chamber assay.
The cells migrated through a polystyrene-membrane with 8 μm-size
pores were stained with calcein-AM, a ﬂuorescence dye, and mea-
sured with a ﬂuorescence reader. As shown in Fig. 1A, nitrotyrosine
signiﬁcantly increased AoSMC migration in a concentration-depen-
dent manner with the maximum effect at 3000 nM (up to 157%compared with the L-tyrosine control, Pb0.01, n=4). The L-tyrosine
treatment had no effect on AoSMC migration compared with the
medium alone control. As a positive control, PDGF-BB signiﬁcantly
increased AoSMC migration up to 198%. The cells that had migrated
to the lower chamber were also visualized under a ﬂuorescence
microscope (Fig. 1B). To conﬁrm the above ﬁnding, we performed a
time course study at 4, 8, 16 and 24 h, and observed a detectable
effect of nitrotyrosine (300 nM) on cell migration as early as 4 h after
cell seeding, and the signiﬁcant effect was observed at 8, 16 and 24 h
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on AoSMC viability and proliferation as tested by a non-radioactive
MTS assay (data not shown).
To further conﬁrm the effect of nitrotyrosine on AoSMC migra-
tion, a cell wound healing assay was used to show the cell mor-
phology and migration behavior after treatment of nitrotyrosine
(300 nM) or L-tyrosine (300 nM). As shown in Fig. 1D, nitrotyrosine
substantially promoted the cell migration during the cell woundFig. 5. Role of ERK1/2 activation in nitrotyrosine-induced AoSMC migration. ERK2 phospho
(300 nM), with or without the presence of SeMet (20 µM) orMnTBAP (3 µM). The cell lysates w
determined by Bio-Plex luminex immunoassay (A) or western blot (B). Ratio of phosphorylate
blot protein bands. The band density was normalized to β-actin levels. n=3. (D) Effect of ER
seeded onto the transwell plate and incubated with nitrotyrosine (300 nM) or L-tyrosine (3
incubation, AoSMC migrated to the lower chamber were measured by calcein-AM staining
Effects of antioxidant SeMet and ERK1/2 inhibitor on nitrotyrosine-induced mRNA expressi
onto the transwell plate and incubated with nitrotyrosine (300 nM) or L-tyrosine (300 nM)
10 µM). After 24 h incubation, cells were harvested. The cDNAwas synthesized from total mRN
integrinαV, and MMP2 were analyzed by real-time PCR and were normalized to the houseke
controls (L-tyrosine). Each bar represents the mean ± SEM. ⁎Pb0.05 compared with the conhealing process compared with the L-tyrosine control, although this
effect was less than the positive control PDGF-BB (10 ng/ml).
3.2. Nitrotyrosine increases the expression of PDGFR-B, MMP2, and
integrins in AoSMC
PDGF-BB mediated through its receptor PDGFR-B, is a major reg-
ulator of smooth muscle cell proliferation and migration. MMP andrylation. Serum-starved AoSMC were treated with nitrotyrosine (300 nM) or L-tyrosine
ere harvested at different time points as indicated. Phosphorylated and total ERK2were
d and total ERK2 proteins in each samplewas calculated. (C) Quantitation of thewestern
K1/2 inhibitor on nitrotyrosine-induced AoSMC migration. Serum-starved AoSMC were
00 nM), with the presence or absence of ERK1/2 inhibitor (PD98059, 10 µM). After 24 h
and quantitation. Results are expressed as percentage of controls (L-tyrosine). n=4. (E).
on of several key cell migration-related molecules. Serum-starved AoSMC were seeded
, with the presence or absence of either SeMet (20 µM) or ERK1/2 inhibitor (PD98059,
A of the treated cells by reverse transcription. ThemRNA levels of PDGFR-B, integrin β3,
eping gene β-actin as [2(Ct β-actin−Ct gene of interest)]. Values are expressed as percentage of
trol (L-tyrosine). n=3 per group.
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of PDGFR-B, MMP and integrins in AoSMC by nitrotyrosine, L-tyrosine
treatment or medium alone treatment was evaluated by real-time PCR.
As shown in Fig. 2A, L-tyrosine has no effect on the expression of these
migration markers compared with medium alone treatments, which
were consistent with the functional assay. However, nitrotyrosine
signiﬁcantly increased the mRNA levels of PDGFR-B, MMP2, integrin
β3 and αV up to 174%, 162%, 221%, and 214%, respectively, compared
with the L-tyrosine-treated controls (100%; Pb0.05; n=3).
Western blotting and quantitation demonstrated that nitrotyro-
sine increased protein levels of PDGFR-B, integrin αV, and integrin β3
expression up to 241%, 228% and 173%, respectively, compared with
the L-tyrosine treatment (100%, Fig. 2B). Nitrotyrosine signiﬁcantly
increased MMP2 activity in a concentration-dependent manner with
the maximal effect up to 245% compared with the L-tyrosine-treated
control (100%, Pb0.01, n=3, Fig. 2C). Thus, we demonstrated that
nitrotyrosine upregulates the VSMC migration-related molecules
such as PDGFR-B, MMP2, and integrins at both mRNA and protein
levels.
3.3. ROS production is involved in nitrotyrosine-inducedAoSMCmigration
To explore whether ROS could be involved in the molecular
mechanism of nitrotyrosine-induced AoSMC migration, we exam-
ined the effects of nitrotyriosine on ROS generation and antiox-
idant application. ROS generation was determined by DCFHDA
oxidation assay [16,17]. With ﬂow cytometry analysis, nitrityrosine
treatment for 30 min signiﬁcantly increased DCFHDA oxidation up
to 180% of MFI compared to L-tyrosine treatment (100%, Pb0.05,
n=4, Fig. 3A). These data were also conﬁrmed by a ﬂorescence
plate reader showing that nitrityrosine signiﬁcantly increased
DCFHDA oxidation up to 145% compared with L-tyrosine controls
(100%, Pb0.05, n=4, Fig. 3B). These data indicate that nitrotyrosine
can induce a transient ROS production, which might be involved in
the signaling pathway of the nitrotyrosine-induced increase in cell
migration.Fig. 6.Nitrotyrosine uptake byAoSMC. Cellswere treatedwith nitrotyrosine (300, 3000 nM) o
using a nitrotyrosine antibody and recognized by FITC-conjugated secondary antibody (gre
ﬂorescence microscope at 40× magniﬁcation.MnTBAP is a speciﬁc superoxide anion scavenger and SeMet is a
well characterized antioxidant. Both antioxidants effectively blocked
nitrotyrosine-induced ROS generation (Fig. 3A and B). Furthermore,
SeMet (20 µM) and MnTBAP (3 µM) effectively blocked nitrotyrosine-
induced AoSMC migration (Pb0.01, n=4, Fig. 4A and B). These data
indicate that ROS plays an important role in nitrotyrosine-induced
AoSMC migration.
3.4. Nitrotyrosine increases the expression of NADPH oxidase subunits in
AoSMC
Oxidative stress could result from upregulation or activation of ROS
generating enzymes. To test whether thesemolecules could play a role
in nitrotyrosine-induced oxidative stress, we determined expressions
of NADPH oxidase subunits, amajor ROS generating enzyme in AoSMC.
Treatment with nitrotyrosine increased the expression of NADPH
oxidase subunit p47phox in AoSMC compared with that with L-tyrosine
(Fig. 4C). At 300 nM of nitrotyrosine, the protein level of p47phox was
signiﬁcantly increased by 60% compared with that of L-tyrosine
(Pb0.05, n=3, Fig. 4C). However, the expression of p22phox in protein
levels did not show any obvious changes between the nitrotyrosine-
treated and tyrosine-treated cells (data not shown).
3.5. ERK1/2 activation is involved in nitrotyrosine-induced
AoSMC migration
Since the activation of MAPKs can be triggered by oxidative stress
through direct or indirect mechanisms [18,19], we investigated
whether MAPKs could be activated in nitrotyrosine-treated cells and
involved in the nitrotyrosine-induced cell migration. Major MAPKs
include ERK1/2, p38, and JNK. Serum-starved AoSMC were incubated
with nitrotyrosine (300 nM) and L-tyrosine (300 nM), and the cell
lysates were collected at different time points. A Bio-Plex luminex
assay (Bio-Rad) was used to detect phospho- and total proteins of
ERK2, p38 and JNK. The ratio of phosphoproteins to total proteins at
each time point was used to evaluate the phosphorylation levels ofr L-tyrosine (3000 nM) for 24 h, and nitrotyrosinewas detected by immunocytochemistry
en). DAPI was used to stain nuclei of the cells (blue). The cells were observed under a
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substantially increased ERK2 phosphorylation with a peak up to 5.11-
fold at 5 min, whereas L-tyrosine (300 nM) had very limited effects on
ERK2 phosphorylation. However, nitrotyrosine (300 nM) had no
signiﬁcant effects on p38 and JNK phosphorylation (data not shown).
In addition, nitrotyrosine-induced ERK2 phosphorylation was con-
ﬁrmed by western blot analysis (Fig. 5B). These results suggest that
nitrotyrosine can activate ERK1/2 signaling pathways on AoSMC. Two
antioxidants, SOD mimetic (MnTBAP) and SeMet, effectively blocked
nitrotyrosine-induced increase in ERK2 phosphorylation levels by
30% and 60%, respectively, in AoSMC at 30 min. However, these anti-
oxidants did not blocked nitrotyrosine-induced increase in ERK2
phosphorylation levels at 10 min (Fig. 5B and C).
To further test the impact of ERK1/2 activation in the promoting
effect of nitrotyrosine on AoSMC migration, we incubated AoSMC
with an ERK1/2 speciﬁc inhibitor (PD98059) for 1 h prior and during
nitrotyrosine or L-tyrosine treatment. Cell migration was evaluated by
the modiﬁed Boyden chamber assay. As shown in Fig. 5D, PD98059
(10 μM) completely blocked the promoting effect of nitrotyrosine on
AoSMC migration (Pb0.01, n=4).
We also found that PD98059 (10 μM) as well as SeMet signiﬁcantly
blocked nitrotyrosine-induced mRNA expression of migration-related
molecules including PDGFR-B, integrins (αV and β3) and MMP2
(Pb0.05, n=3, Fig. 5E). These ﬁndings suggest that nitrotyrosine
promotes AoSMC migration through the ERK1/2 signaling pathway.
3.6. AoSMC uptake nitrotyrosine in a concentration-dependent manner
To address the cellular effect of nitrotyrosine on AoSMC, we de-
tected nitrotyrosine in AoSMC by immunocytochemistry after nirotyr-
osine treatment (300–3000 nM) for 24 h. AoSMC was able to uptake
nitrotyrosine in a concentration-dependent manner (Fig. 6). The up-
take was partially blocked by co-treatment with tyrosine. These data
indicate that nitrotyrosine might act by the intracellular mechanism,
which is consistent with previous observations in other types of cells
[20].
4. Discussion
Although there is a clinical association betweennitrotyrosineplasma
level and cardiovascular disease, the direct roles of nitrotyrosine in
vascular functions have received limited attention. In the current study,
we demonstrated that nitrotyrosine promotes human AoSMCmigration
in a concentration- and time-dependent manner. In addition, nitrotyr-
osine increases the expression of SMCmigration-relatedmolecules such
as PDGFR-B, MMP2 and integrins αV and β3 at both mRNA and pro-
tein levels. Furthermore, we have found that nitrotyrosine induces a
transient ROS production in AoSMC and activates ERK1/2 signal path-
way. These ﬁndings provide a direct link between nitrotyrosine and
smooth muscle cell migration which may contribute to cardiovascular
disease.
Although it is not clear how much free nitrotyrosine is present in
plasma, increased levels of free nitrotyrosine are observed in patients
with many pathological conditions such as rheumatoid arthritis [21],
liver transplantation [22], septic shock [23], and amyotrophic lateral
sclerosis [24]. Free nitrotyrosine was implied in the hemodynamic
responses in vivo [25], and cell growth and morphological changes in
vitro [26,27]. In addition, an increase in the proportion of nitrotyrosine
from 2% of net free tyrosine in controls to 6% in the mice carrying
mutated SOD occurs at the onset of clinical symptoms [28]. Thus, free
nitrotyrosine may play an important role in certain pathogenesis
processes.
The human circulating free nitrotyrosine level varies depending on
the detectingmethod. It is reported to be in a range between7.6±1.4 nM
and 21.2±4.6 nM in normal population [29,30]. Although different
detection methods reported different plasma levels of nitrotyrosinein normal individuals [31–33], patients with coronary artery disease
showed a 1-fold increase of plasma levels of nitrotyrosine compared
with normal controls [34]. The plasma level of nitrotyrosine correlates
with the level of glycemia [35] and the presence of peripheral vascular
disease [36]. In the current study, we found that nitrotyrosine promotes
AoSMC at a concentration range of 30–300 nM (nmol/l), which are
clinically relevant.
Migration and proliferation of VSMC are crucial events in the de-
velopmentof restenosis and atherosclerosis. Especially, VSMCmigration
from the media into the intima contributes to the formation of athero-
sclerotic plaque [37]. These vascular lesions require the interaction
of cell surface integrin receptors with the surrounding extracellular
matrix [38]. Integrins are a family of heterodimeric transmembrane
glycoproteins consistingof noncovalently associatedα andβ chains. The
integrin complexes αVβ3 and αVβ5 have been shown to be expressed
on VSMC and to regulate their migration through interactions with the
extracellular matrix [39]. In the current study, we found that free
nitrotyrosine not only directly promotes human AoSMC migration but
alsoupregulates the expressionof several integrins includingαVandβ3,
aswell as PDGFR-B andMMP2. Thesemolecules couldbe responsible for
the nitrotyrosine-induced AoSMC migration.
Other in vitro studies showed that free nitrotyrosine (100–500 µM)
induced alterations in cellular morphology and increased permeability
in epithelial cell line [40], and led to cell cycle arrestwith decreasedDNA
synthesis in rat aortic smooth muscle cells [41]. In the current study, we
tested the effect of nitrotyrosine (0.3–3000 nM) or L-tyrosine (3000 nM)
on AoSMC viability and proliferation byMTS assay, and however, we did
not detect any changes of cell viability and proliferation in AoSMC com-
pared with non-treated controls (data not shown). These discrepancy
results may result from the different concentrations used in our study
(3 µM) and in other publications (100–500 µM). Cell types or culture
conditions may also differ between our studies and other publications.
Oxidative stress is a state in which excess ROS overwhelms en-
dogenous antioxidant systems. The effects of oxidative stress on the
endothelium and VSMC include direct oxidation and nitration of
proteins and indirect modulation of kinase pathways, such as PKC,
ERK, Src, and Pho [10]. Many factors such as cytokine, drugs, and extra-
cellular inﬂammation factors could increase ROS generation to regulate
cellular reaction such as cell proliferation and migration [11]. In the
current study, we demonstrate that nitrotyrosine can increase the
generation of ROS in AoSMC after 30 min treatment by a speciﬁc ROS
assay (DCFHDA oxidation). More importantly, antioxidants (MnTBAP
and SeMet) were shown to be able to block nitrotyrosine-induced ROS
generation and inhibit the promoting effect of nitrotyrosine on AoSMC
migration. These ﬁndings indicate that ROS play an important role in the
biological activities of free nitrotyrosine in the vascular cells. Our study
also showed that thenitrotyrosine-inducedROSgenerationmightbe the
result of upregulation of NADPH oxidase subunit p47phox in AoSMC.
MAPKs are activated by growth factors and other signaling mol-
ecules, and are critical in signaling pathways mediating cellular pro-
liferation and migration [42]. Iwagaki et al. reported that nitrotyrosine
induced signiﬁcantly greater phosphorylation of ERK1/2 in rat lung
lysates and phosphorylated ERK proteins co-immunoprecipitated with
nitrotyrosine. It suggests that tyrosine nitration might directly activate
the ERK signaling pathway [43,44]. In our current study, we found that
nitrotyrosine transiently increased ERK2 phosphorylation levels, but
not p38 and JNK, and peak response was at 10 min after treatment of
nitrotyrosine by both Bio-Plex luminex and western blot analyses. Two
antioxidants, SOD mimetic (MnTBAP) and SeMet, effectively blocked
nitrotyrosine-induced increase in ERK2 phosphorylation levels in
AoSMC at 30min, but not at 10min. The reason for the delayed blocking
effects of these two antioxidants is not known. It might be possible
that antioxidants could accelerate dephosphorylation of ERK2. This
hypothesis is supported by a recent study with human myeloblastic
leukemia cell line (ML-1), where 12-O-tetradecanoyl-phorbol-13-
acetate (TPA) increased ERK1/2 phosphorylation through increased
1583H. Mu et al. / Biochimica et Biophysica Acta 1783 (2008) 1576–1584H2O2 production, while antioxidant N-acetylcysteine (NAC) blocked
TPA action via inducing a marked and a rapid dephosphorylation of
ERK1/2, suggesting a regeneration of ERK1/2-directed phospahatase
activity by NAC [45]. Furthermore, we found ERK2 phosphorylation
had a functional signiﬁcance because the speciﬁc ERK1/2 inhibitor
PD98059 completely inhibited the promoting effect of nitrotyrosine
on AoSMC migration. However, ERK inhibitor did not affect tyrosine-
treated control cells because EKR1/2 is not activated. Basic cell
migration activity in tyrosine-treated cells may be mediated by other
mechanisms, but not ERK1/2 MAPK [46]. These data indicate that the
activation of the ERK signaling pathway is essential for nitrotyrosine-
induced AoSMC migration. Our data are consistent with the other
reports that ERK1/2 is involved in regulating VSMC proliferation and
migration [38,39,47].
The current study was designed to simulate the clinical situation of
increased circulation nitrotyrosine in inﬂammation conditions regard-
less of the source of nitrotyrosine. Our experimental data support
our hypothesis that free nitrotyrosine may increase SMC migration
through oxidative stress, which may contribute to the vascular lesion
formation. However, we did not address the speciﬁc issue about the
potential effect of intrinsic nitrotyrosine generated from SMCs under
oxidative stress on the cellmigration. In order to directly link increased
superoxide anion to SMC migration, several studies have demon-
strated that 6-anilino-5,8-quinolinequinone (LY83583), a well known
superoxide generator [48,49], can increase SMC migration [50,51].
However, intrinsic levels of nitrotyrosine after LY83583 treatment are
not clear. Further studies of the relationship between superoxide and
intrinsic nitrotyrosine as well as their functional roles in SMC mi-
gration are warranted.
In summary, the results of the present study show that free
nitrotyrosine exerts direct effects on human AoSMC by promoting
cell migration and upregulating PDGFR-B, integrins αV and β3, and
MMP2. The action of nitrotyrosine may be mediated by increasing ROS
production and activating the ERK1/2 signal pathway. Our ﬁndings
provide direct evidence that nitrotyrosine is a biologic active molecule,
which may contribute to the pathogenesis of cardiovascular disease.
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